Drugs Made In America Acquisition Corp Rights
DMAAR
24 hedge funds and large institutions have $2.22M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
26% more funds holding
Funds holding: 19 → 24 (+5)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
12% less capital invested
Capital invested by funds: $2.53M → $2.22M (-$312K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$250K |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
+$81.5K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$73.3K |
| 4 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$64.3K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$27.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2.4K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$1.56K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$257 |
DMAAR Hedge Fund Activity: Q2 2025 in Review
24 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q2 2025, worth a combined $2.22M — down 12% from $2.53M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMAAR positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $250K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $2.4K sold.
- 24 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q2 2025, up from 19 in Q1 2025.
- Funds reported $2.22M of Drugs Made In America Acquisition Corp Rights stock for Q2 2025, down 12% quarter-over-quarter.
- 6 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q2 2025 and 1 closed out, a net change of +5 holders.
- The largest Drugs Made In America Acquisition Corp Rights buyer in Q2 2025 was Toronto Dominion Bank, an estimated $250K added.
- The largest Drugs Made In America Acquisition Corp Rights seller in Q2 2025 was Warberg Asset Management, an estimated $2.4K sold.
Based on aggregated 13F filings for Q2 2025.